We’ve spent billions chasing a dementia cure, only to hit one dead end after another. However, sometimes progress comes from ...

It’s common. One in three people in the United States will have shingles in their lifetime. The risk rises after 50 and patients say it’s nothing like the chicken pox they had as children. Kelli Olson ...

Merck reported fourth-quarter earnings and revenue that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. But Merck posted a modest 2026 outlook that ...

Merck forecasts 2026 sales below Wall Street estimates Co plans to offer clarity on $70 billion growth opportunities by 2027 Merck anticipates $2.5 billion impact from generic competition, Medicare ...

Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its post-Keytruda future with what it foresees as a host of major sales ...

Merck on Tuesday revealed a lower-than-expected outlook for 2026 as the drugmaker aims to remake its business before its powerhouse cancer drug loses patent protection in a few years. The stock MRK ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Chairman and CEO Robert Davis emphasized the company's portfolio transformation, highlighting, "In 2025, our business benefited from successful new product launches, the advancement of important ...

Merck (MRK) shares slid about 3% in premarket trading on Tuesday after the drugmaker issued a full-year 2026 outlook that came in below Wall Street expectations. The Rahway, New Jersey–based company ...

Robert Davis, Merck CEO, joins 'Mad Money' host Jim Cramer to talk quarterly results, global sales growth, recent acquisitions, and more. Got a confidential news tip? We want to hear from you. Sign up ...

For all its success across a wide range of cancer types, Merck’s PD-1 superstar Keytruda has never been able to crack the code for one of the toughest-to-treat indications in oncology—ovarian cancer.

German Merck has set up a new collaboration with U.K. medtech company Calla Lily Clinical Care to work on its next-generation intravaginal drug delivery approach. London-based Calla Lily is working on ...